Molecular docking studies have suggested that FXR serves as a target for Nigakinone, and inhibition of FXR diminishes the protective effects of Nigakinone, highlighting its role in the modulation of the FXR/NLRP3 signaling pathway in the context of colitis (Liu F. et al., 2023). This evidence concerns the gene NLRP3 and colitis.